

RECEIVED

FEB 04 2003

#13

TECH CENTER 1600/2800

PATENT

Customer No. 22,852

Attorney Docket No. 08702.0083-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
Man Sung Co et al. )  
) Group Art Unit: 1641  
Application No.: 09/501,102 )  
) Examiner: Not yet assigned  
Filed: February 9, 2000 )  
)  
CPA Filed: November 21, 2000 )  
)  
For: HUMANIZED IMUNOGLOBULIN )  
REACTIVE WITH B7 MOLECULES )  
AND METHODS OF TREATMENT )  
THEREWITH )

Commissioner for Patents  
Washington, DC 20231

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: February 3, 2003


By:   
E. Stewart Mittler  
Reg. No. 50,316

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08702.0083-00000	Appln. No.	09/501,102
Applicant	Co et al.		
Filing Date	February 9, 2000	Group:	1641



U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
		4,816,397	3/28/89	Boss et al.	435	68	
		4,816,567	3/28/89	Cabilly et al.	530	387	
		4,946,778	8/7/90	Ladner et al.	435	69.6	
		5,225,539	7/6/93	Winter	530	387.3	
		5,476,786	12/19/95	Huston	435	252.33	
		5,514,548	5/7/96	Krebber et al.	435	6	
		5,530,101	6/25/96	Queen et al.	530	387.3	

RECEIVED

FEB 04 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
		WO 86/01533	3/13/86	PCT			in English
		WO 88/07089	9/22/88	PCT			in English
		WO 89/07142	8/10/89	PCT			in English
		WO 93/06213	4/1/93	PCT			in English
		WO 94/29351	12/22/94	PCT			in English
		WO 95/03408	2/2/95	PCT			in English
		WO 96/14865	5/23/96	PCT			in English

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

*Alegre et al.*, Immunomodulation of Transplant Rejection Using Monoclonal Antibodies and Soluble Receptors, Digestive Diseases and Sciences 40:58-64 (1995).

*Bird et al.*, Single-chain Antigen-binding Proteins, Science, 242:423-426 (1988).

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

## INFORMATION DISCLOSURE CITATION



Atty. Docket No.	08702.0083-00000	Appln. No.	09/501,102
Applicant	Co et al.		
Filing Date	February 9, 2000	Group:	1641

## U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,585,089	12/17/96	Queen et al.	424	133.1	
	5,624,821	4/29/97	Winter et al.	435	69.6	
	5,648,260	7/15/97	Winter et al.	435	252.3	
	5,693,761	12/2/97	Queen et al.	536	23.53	
	5,693,762	12/2/97	Queen et al.	530	387.3	
	5,747,034	5/5/98	de Boer et al.	424	137.1	
	5,834,597	11/10/98	Tso et al.	530	387.3	

## FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
EP 0 120 694 ✓	10/3/84	EPO			in English
EP 0 125 023 ✓	11/14/84	EPO			in English
EP 0 194 276 ✓	9/17/86	EPO			in English
EP 0 239 400 ✓	9/30/87	EPO			in English
EP 0 519 596 ✓	12/23/92	EPO			in English


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>Bree et al.</i> , Humanized Anti-B7.1 and Anti-B7.2 Antibodies Prevent Antigen Specific Induction of Immunity in Nonhuman Primates Immunized with Tetanus Toxoid and Mumps Virus Vaccine, Blood 94(10):439a, abstract #1948 (1999).
<i>Co et al.</i> , Humanized Antibodies for Antiviral Therapy, PNAS 88:2869-2873 (1991). ✓

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08702.0083-00000	Appln. No.	09/501,102
Applicant	Co et al.		
Filing Date	February 9, 2000	Group:	1641



RECEIVED

FEB 14 2003


TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	<i>Cole et al.</i> , Human IgG2 Variants Of Chimeric Anti-CD3 Are Nonmitogenic to T Cells, <i>J. Immunol.</i> 159:3613-3621 (1997).
	<i>Ellison et al.</i> , Linkage and Sequence Homology of Two Human Immunoglobulin $\gamma$ Heavy Chain Constant Region Genes, <i>PNAS</i> 79:1984-1988 (1982).
	<i>Hathcock et al.</i> , Role of the CD28-B7 Costimulatory Pathways in T Cell-Dependent B Cell Responses, <i>Advances in Immunology</i> , 62:131-166 (Frank Dixon, ed. 1996).
	<i>He et al.</i> , Humanization and Pharmacokinetics of A Monoclonal Antibody With Specificity For Both E- And P-Selectin, <i>J. Immunol.</i> 160:1029-1035 (1998).
	<i>Kammann et al.</i> , Rapid Insertional Mutagenesis Of DNA By Polymerase Chain Reaction (PCR), <i>Nucl. Acids Res.</i> 17:5405 (1989).
	<i>Kaufman et al.</i> , Improved Vectors For Stable Expression Of Foreign Genes In Mammalian Cells By Use Of The Untranslated Leader Sequence From EMC Virus, <i>Nucl. Acids Res.</i> 19:4485-4490 (1991).
	<i>Kettleborough et al.</i> , Humanization Of A Mouse Monoclonal Antibody By CDR-Grafting: The Importance Of Framework Residues On Loop Conformation, <i>Protein Engineering</i> 4:773-783 (1991).
	<i>Kolbinger et al.</i> , Humanization Of A Mouse Anti-Human IgE Antibody: A Potential Therapeutic For IgE-Mediated Allergies, <i>Protein Engineering</i> 6(8):971-980 (1993).
	<i>Lenschow et al.</i> , Differential Effects of Anti-B7-1 and Anti-B7-2 Monoclonal Antibody Treatment on the Development of Diabetes in the Nonobese Diabetic Mouse, <i>J. Exp. Med.</i> 181:1145-1155 (1995).
	<i>Lenschow et al.</i> , Inhibition of Transplant Rejection Following Treatment with Anti-B7-2 and Anti-B7-1 Antibodies, <i>Transplantation</i> 60:1171-1178 (1995).
	<i>Manheimer-Lory et al.</i> , Molecular Characteristics of Antibodies Bearing an Anti-DNA-Associated Idiotypic, <i>J. Exp. Med.</i> 174:1639-52 (1991).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

## INFORMATION DISCLOSURE CITATION

Atty. Docket No. 08702.0083-00000	Appln. No. 09/501,102
Applicant Co et al.	
Filing Date February 9, 2000	Group: 1641



FEB 04 2003

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		TECH CENTER 1800/2901
	<i>Queen et al.</i> , A Humanized Antibody That Binds To The Interleukin 2 Receptor, PNAS 86:10029-10033 (1989). ✓	
	<i>Reiser et al.</i> , Costimulatory B7 Molecules In The Pathogenesis of Infectious and Autoimmune Diseases, New England J. of Med. 335(18):1369-1377 (1996). ✓	
	<i>Sato et al.</i> , Reshaping a Human Antibody To Inhibit The Interleukin 6-Dependent Tumor Cell Growth, Cancer Research 53:851-856 (1993). ✓	
	<i>Tempest et al.</i> , Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection In Vivo, Biotechnology 9:266-271 (1991). ✓	
	<i>Wettendorff et al.</i> , Generation of Humanized Fab Fragments of B7-24 mAb, an Antibody with Potential Use in the Prevention of Graft Rejection and Development of Graft-Verus-Host Disease, Med. Fac. Landbouww. Univ. Gent., 60(4a-b):2057-2063 (1995). ✓	

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce